OpenBitOpenBit
中文

Biotech: 392 constituents and 40 theses

Constituents and related research views from one data snapshot. Not live quotes or trading advice.

Industry · HY35201010

Performance band in this snapshot

Pulling back

Snapshot returns: 1 day -0.63% · 5 trading days -2.51% · 20 trading days +14.79% · Trading day:

Biotech theses (40)

Research views compiled by the engine, including drivers shared across companies or sectors. Not every one has been confirmed for every constituent.

  • Zipalertinib First-Line EGFR Exon 20 NSCLC Approval Path

    The positive Phase 3 endpoint and longest observed median progression-free survival support continued progression toward an NDA and potential approval.

    Driver data date:

    Status on record: Emerging

    • CGEM: Zipalertinib's clinical efficacy and regulatory progression directly affect the valuation of Cullinan Therapeutics through the potential value of its development program.

  • Will litifilimab improve cutaneous lupus outcomes?

    The Phase 2 evidence supplied shows treatment effects emerging within four weeks and continuing through Week 52, including a reported 27.2% clear-or-utmost-clear skin endpoint.

    Driver data date:

    Status on record: Emerging

    • BIIB: Litifilimab clinical efficacy can affect Biogen's valuation through the potential value of the drug program.

  • Can MangoRx commercialize its antiviral IP with non-dilutive funding?

    The protected MGX-0024 portfolio and staged strategic investment support continued commercialization, while execution remains to be demonstrated.

    Driver data date:

    Status on record: Emerging

    • MGRX: Successful commercialization of the protected MGX-0024 antiviral technology could affect MGRX revenue; the associated investment also provides balance-sheet funding without common-stock issuance.

  • Will UTHR’s patent enforcement constrain Liquidia competition?

    The court has ruled that Liquidia infringes claims 1 and 14 of UTHR’s '327 patent, while the final judgment remains pending.

    Driver data date:

    Status on record: Emerging

    • UTHR: Patent enforcement can protect UTHR’s competitive position and revenue opportunity against Liquidia.

  • Ascendis Licensed-Product Economics

    Ascendis has licenses for the named products and will pay BioMarin royalties on sales, creating a material contractual deduction from product economics through May 2030.

    Driver data date:

    Status on record: Emerging

    • ASND: Royalties paid to BioMarin reduce Ascendis's retained economics on sales of the licensed products.
    • BMRN: The license arrangement gives BioMarin royalty revenue on applicable sales by Ascendis.

  • Capricor Deramiocel BLA Review and Refined Indication

    The FDA accepted the major amendment and did not issue a Complete Response Letter, but the prior advisory committee effectiveness vote and extended review leave support for the refined indication unresolved.

    Driver data date:

    Status on record: Active

    • CAPR: FDA action on the Deramiocel BLA directly changes Capricor's regulatory status and prospective commercialization path.

  • ELEVIDYS Benefit in Older Ambulatory DMD Patients

    The presented evidence supports clinically meaningful and durable functional benefit in patients treated at ages 8 to 12, alongside a consistent safety profile.

    Driver data date:

    Status on record: Emerging

    • SRPT: Evidence that ELEVIDYS provides durable functional benefit in older ambulatory patients can expand the treatment's clinically usable population and support SRPT revenue; safety evidence also affects adoption.

  • Does QURE’s high-dose treatment durably slow disease progression?

    The supplied analyses support a durable slowing signal, while the 48-month cUHDRS result is weaker and the company identifies missing data and survivor bias as limitations.

    Driver data date:

    Status on record: Emerging

    • QURE: The treatment-efficacy evidence can affect QURE’s valuation through the durability and credibility of its clinical development outcome.

  • Can VYD2311 Improve Comirnaty Immunogenicity Without Added Safety or Interference?

    The supplied study results support higher neutralizing titers from the combination while the reported adverse-event and interference findings remain favorable.

    Driver data date:

    Status on record: Emerging

    • BNTX: The question directly concerns Comirnaty combination performance and could affect BNTX vaccine development and commercial outlook.

  • Can Iovance sustain Amtagvi-led revenue growth?

    The supplied evidence supports a revenue-growth trajectory led by U.S. demand and current manufacturing visibility, with profitability improvement remaining conditional on execution and efficiency gains.

    Driver data date:

    Status on record: Emerging

    • IOVA: The view directly concerns Iovance's raised revenue outlook, demand for its products, manufacturing execution, and progress toward profitability.

  • Trofinetide Patent Protection

    The allowed application supports an emerging view that trofinetide U.S. patent protection may extend to March 2041, but the economic effect remains conditional on patent issuance and enforceable scope.

    Driver data date:

    Status on record: Cooling

    • ACAD: Trofinetide patent protection can extend the period during which ACAD may earn revenue from the protected product and dosing methods.

  • Atebrioz Treatment Trajectory in FOP

    Atebrioz has obtained FDA approval for FOP in adults and pediatric patients aged 12 years and older.

    Driver data date:

    Status on record: Active

    • INCY: Atebrioz approval can affect INCY revenue through treatment availability in the approved FOP population; the supplied corpus does not quantify the resulting exposure.

The first 12 drivers are shown. The full data is in the interactive graph.

Market backdrop from the same snapshot

The confirmed structure is dominated by an oil-supply shock that keeps inflation and policy relief conditional, with the tape showing OIL at its 40-day high, TLT at its 40-day low, and SPX and NDX down 1.90% and 2.07% over 20 sessions while VIX has risen over five sessions. Strong payroll evidence and persistent producer-price pressure preserve rate-hike and long-yield risk, but the core-PPI slowdown and unresolved CPI/FOMC path prevent this from becoming a confirmed collective hiking cycle. Trade barriers are implemented and broadening, crypto has bounced without resolving its leverage reset or breakout acceptance, and the company layer is selective: NIO delivery growth is sustained but decelerating, Tesla's autonomous displacement path remains unresolved, and SpaceX's AI buildout is exploratory despite commercialization evidence.

This is the market-wide backdrop, not a separate conclusion about this sector.

Biotech constituents (392)

This snapshot lists 392 stocks, largest market cap first. The list belongs to this snapshot and is not a live membership table.